Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

Angela Davis, Davis County School nurse, said Monday there is significant illness in the Davis County Schools, but the number of absences is not uncommon for the months of January ...

The number of people under the weather goes up every winter, but the University of Vermont Champlain Valley Physicians Hospital is encouraging people to be vigilant and precautious after experiencing ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory illness that primarily affects infants and older adults, ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a "quad-demic." Here what you can do.

Influenza, RSV, COVID-19 and norovirus have all seen ... at LMPHW and pediatric infectious disease specialist at Norton Children’s, said in a news release. With numerous viruses circulating ...

2 While often linked to infants and young children, RSV poses an even greater risk to older adults due to age and underlying health conditions, potentially leading to severe respiratory illness.

Abrysvo was first approved on May 31, 2023, for prevention of lower respiratory tract disease (LRTD) associated with RSV in adults aged 60 years or more, and has since been approved for the same ...

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...